Á lódáil...
Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic Syndrome
Background and objectives: Atypical hemolytic uremic syndrome (aHUS) is associated with a congenital or acquired dysregulation of the complement alternative pathway that leads to continuous complement activation on host cells causing inflammation and damage. Eculizumab, a humanized mAb against compl...
Na minha lista:
Main Authors: | , , , , , , , |
---|---|
Formáid: | Artigo |
Teanga: | Inglês |
Foilsithe: |
American Society of Nephrology
2009
|
Ábhair: | |
Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2723971/ https://ncbi.nlm.nih.gov/pubmed/19556379 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.01090209 |
Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|